Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population‐Based Cohort Study

Oral bisphosphonates (BPs) are highly effective in preventing fractures and are recommended first‐line therapies for patients with osteoporosis. We identified the incidence and predictors of oral BP treatment failure, defined as the incidence of two or more fractures while on treatment (≥2 FWOT) among users with high adherence. Fractures were considered from 6 months after treatment initiation and up to 6 months after discontinuation. Data from computerized records and pharmacy invoices were obtained from Sistema d‘Informació per al Desenvolupament de l‘Investigació en Atenció Primària (SIDIAP; Catalonia, Spain) and Danish Health Registries (Denmark) for all incident users of oral BPs in 2006‐2007 and 2000‐2001, respectively. Fine and Gray survival models using backward‐stepwise selection (p‐entry 0.049; p‐ exit 0.10) and accounting for the competing risk of therapy cessation were used to identify predictors of ≥2 FWOT among patients having persisted with treatment ≥6 months with overall medication possession ratio (MPR) ≥80%. Incidence of ≥2 FWOT was 2.4 (95% confidence interval [CI], 1.8 to 3.2) and 1.7 (95% CI, 1.2 to 2.2) per 1000 patient‐years (PYs) within Catalonia and Denmark, respectively. Older age was predictive of ≥2 FWOT in both Catalonian and Danish cohorts: subhazard ratio (SHR) = 2.28 (95% CI, 1.11 to 4.68) and SHR = 2.61 (95% CI, 0.98 to 6.95), respectively, for 65 to <80 years; and SHR = 3.19 (95% CI, 1.33 to 7.69) and SHR = 4.88 (95% CI, 1.74 to 13.7), respectively, for ≥80 years. Further significant predictors of ≥2 FWOT identified within only one cohort were dementia, SHR = 4.46 (95% CI, 1.02 to 19.4) (SIDIAP); and history of recent or older fracture, SHR = 3.40 (95% CI, 1.50 to 7.68) and SHR = 2.08 (95% CI: 1.04‐4.15), respectively (Denmark). Even among highly adherent users of oral BP therapy, a minority sustain multiple fractures while on treatment. Older age was predictive of increased risk within both study populations, as was history of recent/old fracture and dementia within one but not both populations. Additional and/or alternative strategies should be investigated for these patients. © 2015 American Society for Bone and Mineral Research.

[1]  P. Vestergaard,et al.  Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective , 2015, Osteoporosis International.

[2]  I. Chiodini,et al.  Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis , 2014, Osteoporosis International.

[3]  C. Cooper,et al.  Predictors of Fracture While on Treatment With Oral Bisphosphonates: A Population‐Based Cohort Study , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  A. LaCroix,et al.  Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW) , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  C. Cooper,et al.  Osteoporosis in the European Union: medical management, epidemiology and economic burden , 2013, Archives of Osteoporosis.

[6]  K. Olsen,et al.  Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs—an analysis using national health databases , 2013, Osteoporosis International.

[7]  C. Cooper,et al.  Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) , 2013, Current medical research and opinion.

[8]  S. Cummings,et al.  Treatment failure in osteoporosis , 2012, Osteoporosis International.

[9]  C. Inderjeeth,et al.  Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments , 2012, Journal of Bone and Mineral Metabolism.

[10]  A. Díez-Pérez,et al.  “Burden of osteoporotic fractures in primary health care in Catalonia (Spain): a population-based study” , 2012, BMC Musculoskeletal Disorders.

[11]  A. Díez-Pérez,et al.  Risk factors for prediction of inadequate response to antiresorptives , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[13]  R. Eastell,et al.  Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study , 2012, Osteoporosis International.

[14]  R. Eastell,et al.  Proton pump inhibitor use and the antifracture efficacy of alendronate. , 2011, Archives of internal medicine.

[15]  O. Ström,et al.  The societal burden of poor persistence to treatment of osteoporosis in Sweden. , 2011, Bone.

[16]  Daniel Prieto-Alhambra,et al.  Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). , 2011, Informatics in primary care.

[17]  M. Saito,et al.  Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus , 2010, Osteoporosis International.

[18]  J. LeLorier,et al.  Differences in persistence among different weekly oral bisphosphonate medications , 2009, Osteoporosis International.

[19]  A. Boskey,et al.  Spectroscopic markers of bone quality in alendronate-treated postmenopausal women , 2009, Osteoporosis International.

[20]  S. Adami,et al.  Osteoporosis treatment and fracture incidence: the ICARO longitudinal study , 2008, Osteoporosis International.

[21]  Anuja Roy,et al.  Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[22]  S. Boonen,et al.  Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.

[23]  S. Cummings,et al.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.

[24]  S. Adami,et al.  Fracture Incidence and Characterization in Patients on Osteoporosis Treatment: The ICARO Study , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  O. Johnell,et al.  An estimate of the worldwide prevalence and disability associated with osteoporotic fractures , 2006, Osteoporosis International.

[26]  C. Cooper,et al.  Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). , 2006, QJM : monthly journal of the Association of Physicians.

[27]  B. Ettinger,et al.  Persistence with weekly alendronate therapy among postmenopausal women , 2006, Osteoporosis International.

[28]  Krista F. Huybrechts,et al.  The impact of compliance with osteoporosis therapy on fracture rates in actual practice , 2004, Osteoporosis International.

[29]  Y. Hundrup,et al.  The validity of self-reported fractures among Danish female nurses: comparison with fractures registered in the Danish National Hospital Register , 2004, Scandinavian journal of public health.

[30]  Jacques P. Brown,et al.  What predicts early fracture or bone loss on bisphosphonate therapy? , 2003, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[31]  Dieter Felsenberg,et al.  Risedronate prevents new vertebral fractures in postmenopausal women at high risk. , 2003, The Journal of clinical endocrinology and metabolism.

[32]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[33]  M. Hochberg,et al.  Alendronate Reduces the Risk of Multiple Symptomatic Fractures: Results from the Fracture Intervention Trial , 2002, Journal of the American Geriatrics Society.

[34]  S. Cummings,et al.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.

[35]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[36]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[37]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.